Dow Jones
35.756,88 +15,73 (+0,04%) Nasdaq
15.235,71 +9,01 (+0,06%) Nikkei 225
28.940,64 -165,37 (-0,57%) EUR/USD
1,1608 +0,0005 (+0,05%) BTC-EUR
52.769,11 -1.452,13 (-2,68%) CMC Crypto 200
1.490,11 -15,04 (-1,00%)
Arch Therapeutics, Inc. (0HHJ.L)
| Chiusura precedente | 0,0706 |
| Aperto | 0,1290 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,1290 - 0,1290 |
| Intervallo di 52 settimane | 0,1290 - 0,1290 |
| Volume | 800 |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | -0,71 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0280 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Arch Therapeutics to Present AC5 Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC) Fall
AC5® Advanced Wound System Selected for Innovation SpotlightFRAMINGHAM, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced that it will be presenting at the 2021 Symposium on Advanced Wound Care (SAWC) Fall. The event is being held at Caesars Palace, Las Vegas, Nevada from October 29-31, 2021. The Company will be discussing AC5® Advanced Wou
- GlobeNewswire
Arch Therapeutics Launches Experts in Wound Care Program
Key Opinion Leaders Share Insights on Advancing Wound CareFRAMINGHAM, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, announced today that it has launched its Experts in Wound Care Program, a series of interviews with key opinion leaders dedicated to advancing wound care. The interviews will focus on important wound care topics, such as how evolving best
- GlobeNewswire
Arch Therapeutics Provides Corporate Update
90-Day Report Card for Commercialization Effort FRAMINGHAM, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today provided a corporate update at the LD Micro Main Event XIV investor conference in Los Angeles, CA. The presentation slides will be publicly available through the SEC website as an attachment to the Form 8-K filed in connection with this press
